ArticleFunctional & integrative genomics2025
Integrated multi-omics analysis and machine learning refine molecular subtypes and prognosis in hepatocellular carcinoma through O-linked glycosylation genes.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prediction of chemoresistance in ovarian cancer based on deep learning with pathological images.Functional & integrative genomics · 2026Article
- O-glycosylation in Cancer: Emerging Paradigms and Prospects for Precision Oncology.International journal of biological sciences · 2026Review
- Machine Learning-Based Sialylation-Associated Gene Signature Predicts Prognosis and Immune Landscape in Hepatocellular Carcinoma: Validation via Multi-Omics Analysis and in vitro Assays.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
O-glycosylation significantly influences cellular physiological processes and disease regulation by modulating the structure, function, and stability of proteins. However, there is a notable gap in research focusing on O-glycosylation in relation to the prognosis of HCC patients. The study aimed to explore the expression and function of O-glycosylation genes in HCC from both bulk- and single-cell perspectives. Multi-omics data related to O-glycosylation identified by weighted gene co-expression network analysis (WGCNA). This was then combined with ten different clustering algorithms to construct molecular subtypes of high-resolution HCC. Cancer subtype 1 (CS1) is characterized by significant genomic variation, moderate immune cell infiltration, and immune function enrichment. Patients with CS2 have a better prognosis and are characterized by a stable genomic structure, an immune-hot phenotype with rich immune cell infiltration, and sensitivity to immunotherapy. CS3 is characterized by poor prognosis, outstanding genomic instability, and an immune-cold phenotype, but can benefit more from treatment with drugs such as sorafenib, cisplatin, paclitaxel, and gemcitabine. To further emphasize the role of O-glycosylation genes in individual HCC patients, we employed 59 machine-learning methods to construct and assess prognostic traits with improved generalizability. Microarray results indicated a pronounced upregulation of glycosylation hub genes involved in HCC stratification and modeling within HCC tumorous tissues. Altogether, our study highlights the importance of O-glycosylation for the assessment of HCC prognosis and treatment options by redefining HCC subtypes and constructing a consensus machine learning-driven prognostic signature (CMLS). This research establishes an optimized decision-making platform that enables the precise stratification of HCC patients, refines tumor treatment plans, and predicts patient survivability, with broad clinical implications.
Indexed as
Identifiers
40719796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.